Catalent Case Management Accelerates Shipment for SCN1A+ Dravet Syndrome Gene Therapy
Summary: Catalent Case Management accelerates the global delivery of ETX101, a breakthrough gene therapy from Encoded Therapeutics, designed to treat SCN1A+ Dravet syndrome. Addressing significant international logistical hurdles and regulatory complexities, Catalent streamlined global shipments from the U.S. to Australia and the U.K., reducing delivery times by up to 78%. This partnership ensured seamless customs clearance, accurate use of Harmonized Tariff Schedule (HTS) codes, and proactive communication, achieving a 100% success rate for timely patient dosing. Learn how Catalent’s tailored, proactive logistics solutions enhance supply chain reliability and support advanced therapies worldwide.